CORRESP Filing
MANGOCEUTICALS, INC.
Date: June 17, 2025 · CIK: 0001938046 · Accession: 0001641172-25-015370
AI Filing Summary & Sentiment
Reasoning
File numbers found in text: 333-287689
Letter
MANGOCEUTICALS, INC.
N. Dallas Parkway, Suite 600
Dallas, Texas 75248
June 17, 2025
VIA EDGAR
U.S. Securities and Exchange Commission
Division of Corporation Finance
F Street, N.E.
Washington, D.C. 20549
Attention: Katherine Bagley
Re: Mangoceuticals, Inc.
Registration Statement on Form S-1
Filed May 30, 2025
File No. 333-287689
Ladies and Gentlemen:
Pursuant to Rule 461 under the Securities Act of 1933, as amended, Mangoceuticals, Inc., hereby requests acceleration of effectiveness of the above referenced Registration Statement on Form S-1 so that it will become effective at 5:00 p.m., Eastern Daylight Time, on Wednesday, June 18, 2025, or as soon thereafter as practicable.
Very
truly yours,
/s/
Jacob D. Cohen
Show Raw Text
CORRESP 1 filename1.htm MANGOCEUTICALS, INC. 15110 N. Dallas Parkway, Suite 600 Dallas, Texas 75248 June 17, 2025 VIA EDGAR U.S. Securities and Exchange Commission Division of Corporation Finance 100 F Street, N.E. Washington, D.C. 20549 Attention: Katherine Bagley Re: Mangoceuticals, Inc. Registration Statement on Form S-1 Filed May 30, 2025 File No. 333-287689 Ladies and Gentlemen: Pursuant to Rule 461 under the Securities Act of 1933, as amended, Mangoceuticals, Inc., hereby requests acceleration of effectiveness of the above referenced Registration Statement on Form S-1 so that it will become effective at 5:00 p.m., Eastern Daylight Time, on Wednesday, June 18, 2025, or as soon thereafter as practicable. Very truly yours, /s/ Jacob D. Cohen Jacob D. Cohen Chairman and Chief Executive Officer cc: Lucosky Brookman LLP